Joanne Dickinson

Dr. Joanne Dickinson

Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1999 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JFJohn H. Fingert
John H. Fingert
EHElise Héon
Elise Héon
JLJeffrey M. Liebmann
Jeffrey M. Liebmann
TYTetsuya Yamamoto
Tetsuya Yamamoto
JCJamie E. Craig
Jamie E. Craig
ESEdwin M. Stoned
Edwin M. Stoned
A glaucoma locus, GLC1A, was identified previously on chromosome 1q. A gene within this locus (encoding the protein myocilin) subsequently was shown to harbor mutations in 2–4% of primary open angle glaucoma patients. A total of 1703 patients was screened from five different populations representing three racial groups. There were 1284 patients from primarily Caucasian populations in Iowa (727), Australia (390) and Canada (167). A group of 312 African American patients was from New York City and 107 Asian patients from Japan. Overall, 61 different myocilin sequence variations were identified. Of the 61 variations, 21 were judged to be probable disease-causing mutations. The number of probands found to harbor such mutations in each population was: Iowa 31/727 (4.3%), African Americans from New York City 8/312 (2.6%), Japan 3/107 (2.8%), Canada 5/167 (3.0%), Australia 11/390 (2.8%) and overall 58/1703 (3.4%). Overall, 16 (76%) of 21 mutations were found in only one population. The most common mutation observed, Gln368Stop, was found in 27/1703 (1.6%) glaucoma probands and was found at least once in all groups except the Japanese. Studies of genetic markers flanking the myocilin gene suggest that most cases of the Gln368Stop mutations are descended from a common founder. Although the specific mutations found in each of the five populations were different, the overall frequency of myocilin mutations was similar (∼2–4%) in all populations, suggesting that the increased rate of glaucoma in African Americans is not due to a higher prevalence of myocilin mutations.

20 September 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
RERosalind Eeles
Rosalind Eeles
TCThe UK ProtecT Study Collaborators
The UK ProtecT Study Collaborators
TCThe PRACTICAL Consortium
The PRACTICAL Consortium
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
DEDouglas F Easton
Douglas F Easton

14 April 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
FAFarzaneh Atashrazm
Farzaneh Atashrazm
RLRay M. Lowenthal
Ray M. Lowenthal
GWGreg Woods
Greg Woods
AHAdele F. Holloway
Adele F. Holloway
Joanne DickinsonJoanne Dickinson
Joanne Dickinson
There is a wide variety of cancer types yet, all share some common cellular and molecular behaviors. Most of the chemotherapeutic agents used in cancer treatment are designed to target common deregulated mechanisms within cancer cells. Many healthy tissues are also affected by the cytotoxic effects of these chemical agents. Fucoidan, a natural component of brown seaweed, has anti-cancer activity against various cancer types by targeting key apoptotic molecules. It also has beneficial effects as it can protect against toxicity associated with chemotherapeutic agents and radiation. Thus the synergistic effect of fucoidan with current anti-cancer agents is of considerable interest. This review discusses the mechanisms by which fucoidan retards tumor development, eradicates tumor cells and synergizes with anti-cancer chemotherapeutic agents. Challenges to the development of fucoidan as an anti-cancer agent will also be discussed.

10 July 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
TCThe PRACTICAL Consortium
The PRACTICAL Consortium
AOAli Amin Al Olama
Ali Amin Al Olama
GGGraham G Giles
Graham G Giles
RERosalind Eeles
Rosalind Eeles

27 April 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
KSK.C. Simon
K.C. Simon
IMI.A.F. van der Mei
I.A.F. van der Mei
KMK.L. Munger
K.L. Munger
APAnne-Louise Ponsonby
Anne-Louise Ponsonby
Joanne DickinsonJoanne Dickinson
Joanne Dickinson
AAA. Ascherio
A. Ascherio
Objective: To examine the interplay between smoking, serum antibody titers to the Epstein-Barr virus nuclear antigens (anti-EBNA), and HLA-DR15 on multiple sclerosis (MS) risk. Methods: Individual and pooled analyses were conducted among 442 cases and 865 controls from 3 MS case-control studies—a nested case-control study in the Nurses9 Health Study/Nurses9 Health Study II, the Tasmanian MS Study, and a Swedish MS Study. Conditional logistic regression models were used to calculate odds ratios (ORs) and 95% CIs for the association between smoking, anti-EBNA titers, HLA-DR15, and MS risk. Study estimates were pooled using inverse variance weights to determine a combined effect and p value. Results: Among MS cases, anti-EBNA titers were significantly higher in ever smokers compared to never smokers. The increased risk of MS associated with high anti-EBNA Ab titers was stronger among ever smokers (OR = 3.9, 95% CI = 2.7–5.7) compared to never smokers (OR = 1.8, 95% CI = 1.4–2.3; p for interaction = 0.001). The increased risk of MS associated with a history of smoking was no longer evident after adjustment for anti-EBNA Ab titers. No modification or confounding by HLA-DR15 was observed. The increased risk of MS associated with ever smoking was only observed among those who had high anti-EBNA titers (OR = 1.7, 95% CI = 1.1–2.6). Conclusions: Smoking appears to enhance the association between high anti-EBNA titer and increased multiple sclerosis (MS) risk. The association between HLA-DR15 and MS risk is independent of smoking. Further work is necessary to elucidate possible biologic mechanisms to explain this finding.

12 October 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
AOAli Amin Al Olama
Ali Amin Al Olama
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
FSFredrick Schumacher
Fredrick Schumacher
FWFredrik Wiklund
Fredrik Wiklund
SBSonja I. Berndt
Sonja I. Berndt
RERosalind Eeles
Rosalind Eeles
Genome-wide association studies (GWAS) have identified multiple common genetic variants associated with an increased risk of prostate cancer (PrCa), but these explain less than one-third of the heritability. To identify further susceptibility alleles, we conducted a meta-analysis of four GWAS including 5953 cases of aggressive PrCa and 11 463 controls (men without PrCa). We computed association tests for approximately 2.6 million SNPs and followed up the most significant SNPs by genotyping 49 121 samples in 29 studies through the international PRACTICAL and BPC3 consortia. We not only confirmed the association of a PrCa susceptibility locus, rs11672691 on chromosome 19, but also showed an association with aggressive PrCa [odds ratio = 1.12 (95% confidence interval 1.03–1.21), P = 1.4 × 10−8]. This report describes a genetic variant which is associated with aggressive PrCa, which is a type of PrCa associated with a poorer prognosis.